QIAGEN launches QCI Secondary Analysis, a new cloud-based secondary analysis solution for oncology and inherited disease applications that enables high-throughput data analysis with limited resource and infrastructure investment.
Next-generation sequencing (NGS) has rapidly gained popularity as a diagnostic testing approach due to its unparalleled ability to comprehensively analyze genetic information with high throughput and precision. However, small and decentralized labs face significant hurdles when it comes to adopting NGS testing. From high upfront costs associated with acquiring the necessary equipment, to the complexity of bioinformatics tools and compliance management that require specialized expertise in data analysis and data security, adopting NGS poses challenges for labs with limited staff and infrastructure.
To empower small and decentralized labs to easily adopt NGS testing, QIAGEN has launched a new secondary analysis solution for oncology and inherited disease applications that enables high-throughput secondary analysis for use with any clinical NGS data. QCI Secondary Analysis is an agnostic, cloud-based software-as-a-service (SaaS) solution that supports all QIAGEN QIAseq panels and seamlessly integrates with QCI Interpret, QIAGEN’s clinical variant interpretation and reporting software, to deliver highly scalable and customizable Sample to Insight workflows for oncology and inherited disease applications.
“Our goal is to empower molecular testing labs, regardless of size, budget, and experience, to leverage the power of comprehensive genomic information to advance precision medicine in every setting. Due to NGS adoption barriers, including complexity and cost, a vast majority of small- to mid-size molecular laboratories rely on limited single-gene tests or choose to outsource sample testing for more comprehensive NGS analysis. However, with the launch of our new NGS secondary analysis software, we are making NGS testing more accessible to decentralized labs.”
Jonathan Sheldon, Senior Vice President of QIAGEN Digital Insights. “
Tweet
“QCI Secondary Analysis is particularly valuable for labs looking to start running NGS-based tests because it’s a turnkey solution with easy-to-use features for the everyday lab technician. With the availability of this new solution, QIAGEN has simplified the whole bioinformatics pipeline, providing an integrated workflow that minimizes resource investment and maximizes productivity.”
Can Koşukcu, Senior Bioinformatics Application Scientist of DiagnoSeq, an early-access customer of QCI Secondary Analysis.
Tweet
Expanding on the QIAGEN Clinical Insights (QCI) portfolio, QCI Secondary Analysis is designed to streamline analysis from a range of assay types, enabling labs to process more sequencing data without extensive time and resource investment. The turnkey solution is deployed on the QIAGEN Clinical Cloud, a secure cloud environment ensuring the highest degree of isolation and data protection, including compliance with ISO 27001, General Data Protect Regulation (GDPR), and the Health Insurance Portability and Accountability Act (HIPPA) requirements.
While QCI Secondary Analysis is a plug-in-play solution that can support any panel, NGS instrument or software, the true value of this new offering is how it complements QIAGEN’s Sample to Insight portfolio. QCI Secondary Analysis is validated for use for all QIAseq panels, can be used with LightSpeed Clinical, a new software module within QIAGEN CLC Genomics Workbench Premium that enables ultra-fast NGS analysis, and directly integrates with QCI Interpret, QIAGEN’s variant interpretation and reporting platform that has been trusted to analyze and interpret more than 3.5 million NGS patient test cases worldwide.
Learn more about QCI Secondary Analysis here.
Every clinical NGS lab is unique. That’s why QIAGEN offers a comprehensive portfolio of secondary analysis solutions designed to meet the needs of each lab. Take our quiz to find out which secondary analysis solution is right for you based on your lab’s computing resources, personnel expertise, and annual sample volume.
Whole-exome sequencing (WES) using next-generation sequencing (NGS) technology is a powerful tool for investigating variants linked to genetic disease. It provides a high-resolution, unbiased view across the entire exome to discover causative variants of inherited disorders. However, the vast amounts of data produced by WES require comprehensive data analysis tools that can efficiently translate the raw sequencing data into meaningful, interpretable results. To address these challenges, QIAGEN Digital Insights offers QCI Interpret Translational.
QCI Interpret Translational is a NGS variant assessment software solution that enables rapid, evidence-powered variant annotation, filtering, and triage for human exome, genome, and large cohort sequencing data. QCI Interpret Translational rapidly identifies the most compelling disease variants in human sequencing data by combining powerful analytical tools and unparalleled content from the QIAGEN Knowledge Base. The QIAGEN Knowledge Base is the industry’s largest collection of biological and clinical findings, with roughly 2,000,000 unique variants expertly curated from over 300,000 scientific articles, including 140,000 variants connected to the top 200 newborn/carrier screening genes.
QCI Interpret Translational enables:
QCI Interpret Translational compiles all gene variants within a dataset and enables this list to be quickly narrowed down through an interactive series of filters. This Interactive Filter Cascade can be adapted to reflect selection criteria of interest and their importance to the research question at hand (Figure 1).
Figure 1. Rapid prioritization of variants. A list of gene variants relevant to an analyzed dataset can be drilled down to those most relevant to the research question by defining a series of filters that reflect the most important selection criteria.
Filters of the QCI Interpret Translational are based on information in the QIAGEN Knowledge Base, including manually curated primary literature on human mutations in patients with particular diseases or abnormal phenotypes. These filters offer a broad portfolio of selection criteria that go above and beyond identifying variants that impact symptoms, pathways, processes and genes implicated in drug response or disease progression.
Additional biologically relevant filters allow, for example, identification of diseases consistent with clinical features and deleterious variants in medical genomes, or use of single and bidirectional statistical burden tests to find genes or pathways with significantly more deleterious variants in one study group compared to another.
Users can access 5 different filters to triage variants with granular control (Figure 2):
Figure 2. Customizable dynamic variant filter. A list of gene variants relevant to an analyzed dataset can be drilled down to those most relevant to the research question by defining a series of filters that reflect the most important selection criteria.
Watch a video tutorial to learn how to use the Interactive Filter Cascade in QCI Interpret Translational here.
Did you know we offer complimentary trials of our software? No restricted features, no sample data – you get to try all the features of QCI Interpret Translational with your data and see how it works.
